Form 4: BioSig Technologies Interim CFO Receives Significant Equity Grant Under 2023 Incentive Plan

BioSig Technologies, Inc. has reported that its Interim CFO, Ferdinand Groenewald, was granted 175,000 shares of common stock, fully vested, under the company's 2023 Equity Incentive Plan.

Summary

• Ferdinand Groenewald, Interim CFO of BioSig Technologies, Inc. (BSGM), acquired 175,000 shares of common stock.
• The transaction occurred on May 29, 2025, and the shares were granted under the Company's 2023 Equity Incentive Plan.
• The shares were fully vested as of the grant date, May 29, 2025.
• The closing price of BioSig Technologies' common stock on the grant date was $5.05 per share.
• Following this transaction, Mr. Groenewald beneficially owns a total of 235,000 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it indicates executive alignment and compensation through equity, which is generally viewed favorably by investors as it ties management's success to the company's stock performance.

Positives

• The grant of 175,000 fully vested shares to the Interim CFO aligns management's interests with those of shareholders, potentially incentivizing long-term performance.
• The transaction demonstrates the company's utilization of its 2023 Equity Incentive Plan to compensate and retain key executives.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or operations.

Industry Context

Equity grants to executives are a standard practice across various industries, particularly in technology and biotech sectors, to attract, retain, and incentivize key personnel by aligning their financial interests with the company's long-term success and shareholder value.

Management Changes

Corporate Governance

Related Party Transactions

• The grant of 175,000 shares of common stock to Ferdinand Groenewald, the Interim CFO, constitutes a related party transaction as it involves compensation to a key executive.

Stakeholder Impact

• Shareholders: Potential for increased alignment between management and shareholder interests, but also minor dilution from the issuance of new shares (if applicable, though often from existing pool).
• Employees: Reflects the company's compensation strategy, potentially influencing morale and retention of other key personnel.

Key Dates

Keywords

BioSig Technologies, BSGM, Form 4, Insider Transaction, Stock Grant, Equity Incentive Plan, Executive Compensation, Ferdinand Groenewald, Interim CFO